Jiangsu Hualan New Pharmaceutical Material Co. Ltd.
Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. engages in the research and development, manufacture, and sale of packaging materials for the pharmaceuticals' industry in China and internationally. It offers covered rubber stoppers serise; halogenated butyl rubber stopper freeze-dryied series; halogenated butyl rubber stopper antibiotics series; halogenated butyl rubber plugs infusion series;… Read more
Jiangsu Hualan New Pharmaceutical Material Co. Ltd. (301093) - Total Assets
Latest total assets as of June 2025: CN¥2.52 Billion CNY
Based on the latest financial reports, Jiangsu Hualan New Pharmaceutical Material Co. Ltd. (301093) holds total assets worth CN¥2.52 Billion CNY as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Jiangsu Hualan New Pharmaceutical Material Co. Ltd. - Total Assets Trend (2019–2024)
This chart illustrates how Jiangsu Hualan New Pharmaceutical Material Co. Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Jiangsu Hualan New Pharmaceutical Material Co. Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
Jiangsu Hualan New Pharmaceutical Material Co. Ltd.'s total assets of CN¥2.52 Billion consist of 67.7% current assets and 32.4% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 16.0% |
| Accounts Receivable | CN¥173.34 Million | 6.9% |
| Inventory | CN¥127.95 Million | 5.1% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥82.29 Million | 3.3% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Jiangsu Hualan New Pharmaceutical Material Co. Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jiangsu Hualan New Pharmaceutical Material Co. Ltd.'s current assets represent 67.7% of total assets in 2024, an increase from 57.4% in 2019.
- Cash Position: Cash and equivalents constituted 16.0% of total assets in 2024, up from 8.1% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, unchanged from 3.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 6.9% of total assets.
Jiangsu Hualan New Pharmaceutical Material Co. Ltd. Competitors by Total Assets
Key competitors of Jiangsu Hualan New Pharmaceutical Material Co. Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Beijing Centergate Technologies Holding Co Ltd
SHE:000931
|
China | CN¥3.82 Billion |
|
Blue Sail Medical Co Ltd
SHE:002382
|
China | CN¥16.46 Billion |
|
Andon Health Co Ltd
SHE:002432
|
China | CN¥28.98 Billion |
|
Allmed Medical Products Co Ltd Class A
SHE:002950
|
China | CN¥5.35 Billion |
|
Inix Technologies Holdings Bhd
KLSE:0094
|
Malaysia | RM72.53 Million |
|
Focus Point Holdings Bhd
KLSE:0157
|
Malaysia | RM328.19 Million |
|
Careplus Group Bhd
KLSE:0163
|
Malaysia | RM286.61 Million |
|
LKL International Bhd
KLSE:0182
|
Malaysia | RM173.46 Million |
Jiangsu Hualan New Pharmaceutical Material Co. Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Jiangsu Hualan New Pharmaceutical Material Co. Ltd. generates 0.23x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Jiangsu Hualan New Pharmaceutical Material Co. Ltd. generates $ 1.98 in net profit.
Jiangsu Hualan New Pharmaceutical Material Co. Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.75 | 11.18 | 12.54 |
| Quick Ratio | 8.90 | 10.51 | 11.86 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.52 Billion | CN¥ 1.58 Billion | CN¥ 2.10 Billion |
Jiangsu Hualan New Pharmaceutical Material Co. Ltd. - Advanced Valuation Insights
This section examines the relationship between Jiangsu Hualan New Pharmaceutical Material Co. Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.00 |
| Latest Market Cap to Assets Ratio | 0.50 |
| Asset Growth Rate (YoY) | -7.6% |
| Total Assets | CN¥2.50 Billion |
| Market Capitalization | $1.26 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Jiangsu Hualan New Pharmaceutical Material Co. Ltd.'s assets below their book value (0.50 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Jiangsu Hualan New Pharmaceutical Material Co. Ltd.'s assets decreased by 7.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Jiangsu Hualan New Pharmaceutical Material Co. Ltd. (2019–2024)
The table below shows the annual total assets of Jiangsu Hualan New Pharmaceutical Material Co. Ltd. from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.50 Billion | -7.63% |
| 2023-12-31 | CN¥2.71 Billion | +5.09% |
| 2022-12-31 | CN¥2.58 Billion | -2.01% |
| 2021-12-31 | CN¥2.63 Billion | +323.56% |
| 2020-12-31 | CN¥621.62 Million | +4.04% |
| 2019-12-31 | CN¥597.50 Million | -- |